Cheetah Medical Inc., a Vancouver, WA, USA-based developer of a non-invasive hemodynamic monitoring system, completed a $14.5m financing.
Backers included Springfield Investments, Ascension Health Ventures, MVM Life Science Partners and Robert Bosch Venture Capital.
The company intends to use the capital to accelerate commercialization of its system – NICOM – in the U.S. and internationally.
Founded in 2000, Cheetah Medical provides NICOM, a noninvasive hemodynamic monitoring system, which is based on its patented and proprietary BIOREACTANCE® technology. NICOM, which is FDA cleared and has received a CE Mark, deploys NICOM for Goal Directed Fluid Management in over 100 hospitals in the U.S. and is used in OUS markets.
The company has also appointed Chris Hutchison as President and CEO and William T. Denman , MBChB, FRCA as Chief Medical Officer.